
Alkeus Pharmaceuticals Presents Positive 24-Month Phase 2 Data for Gildeuretinol in GA at ARVO 2025
Alkeus Pharmaceuticals, Inc. presented additional 24-month results from its Phase 2 SAGA clinical trial of oral gildeuretinol for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The data were featured during …